2Zer M,Madsbad S,Madsen JL,et al.Effect of 6-week course of glucagon-like peptide 1 on glycaemic control,insulin sensitivity,and beta cell function in type 2 diabetes:a parallel group study[J].Lancet,2002,359:824-830.
3Nauck MA,Kleine N,Orskov C,et al.Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin dependent) diabetic patients[J].Diabetologia,1993,36:741-744.
4Juhl CB,Hollingdal M,Sturis J,et al.Beditime administration of NN2211 a long-acting GLP-1 derivative,substantially reduces fasting and postprandial glycemia in type 2 diabetes[J].Diabetes,2002,51 (2):424-429.
5Dunning BE,Foley JE,Ahren B.Alpha cell function in health and disease:influence of glucagon-like peptide-1[J].Diabetologia,2005,48 (9):1700-1713.
6Meneilly GS,Greig N,Tildesley H,et al.Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes[J].Diabetes Care,2003,26(10):2835-2841.
7Vella A,Shah P,Basu R,et al.Effect of glucagons-like peptide 1(7-36)amide on glucose effectiveness aned insulin action people with type 2 diabetes[J].Diabetes,2000,49(4):611-617.
